None listed
Conditions
Interventions
None listed
Sponsors
Eetho Brands Inc
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy females aged between 55 and 65 years with a Body mass index (BMI) ofapproximately 24 and 29 kg/m2. 2.Women with menopausal symptoms (modified Kupperman index scores 15-29), absenceof menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) more than 30mIU/mL; estradiol less than 30 pg/mL. 3.Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) andcalcium carbonate. 4.Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA). 5.Must also be experiencing at least two symptoms of menopause, such as sleepdisturbances, mood changes, fatigue and lack of energy, changes in sexual function,urinary changes, weight gain, or vaginal changes 6.Subject understands the study procedures and provides signed informed consent toparticipate in the study. 7.Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations(including clinical biochemistry, haematology, lipid profile, thyroid profile and completeurinalysis) within the reference range for the testing laboratory or the results are deemednot clinically significant for inclusion into this study by the investigator.
Exclusion criteria
Exclusion criteria: 1.Consumption of functional food or supplement that modifies body composition, during or6 months prior to the study. 2.History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina atany time or thrombophlebitis within the last 5 years. 3 Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions. 4.Presence of chronic diseases that prevent the performance of a physical exercise program(disabling arthropathies, moderate / severe chronic lung disease, arrhythmias, etc.) 5.High alcohol intake (more than 2 standard drinks per day), or recreational drugs (such ascocaine, methamphetamine, marijuana, etc.) or psychiatric drug users. 6.Smokers or tobacco users. 7.Inability to understand informed consent. 8.Serious or terminal illnesses. 9.Fasting blood glucose level more than 125 mg/dl. 10.Subjects with a high blood pressure at screening (systolic blood pressure more or equalto 140 mmHg or diastolic blood pressure more or equal to 90 mmHg). 11. Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months. 12.Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushings syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months. 13.Taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects). 14. Active gall bladder disease, gynaecological (including hysterectomy) or breast surgery in the last 6 months. 15. Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure. 16. Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases. 17. History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years. 18.History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products. 19.History of positive hepatitis screening including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and or syphilis. 20. History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. 21.Participated in a clinical study with an investigational drug or biologic within the last 30 days. 22. Any condition that in opinion of the investigator, does not justify the subjects participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4) Timepoint: Screening, Day 180, Day 360 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to the end of the study period in Scores ofmodified Kupperman index (mKI)Timepoint: Screening, Baseline, Day 90,Day 180,Day 360;Change from baseline to the end of the study period in Lean bodymass through DEXATimepoint: Screening,Day 180, Day 360;Change from baseline to the end of the study period in Hand grip-strengthTimepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in ChalderFatigue Scale (CFS)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Profile ofMood States (POMS-SF)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in FemaleSexual Function Index (FSFI)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in PittsburghSleep Quality Index (PSQI)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in MenopauseSymptoms Severity Inventory (MSSI-38)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Mini CogQuestionnaire (Cognitive function)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Scores ofsubjective self-assessment on hair qualityTimepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Nail qualityrelated questionnaire (NailQoL)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period inGastrointestinal symptoms questionnaire (GIS)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in PerceivedStress Scale (PSS-10)Timepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Visualassessment of skin wrinklesTimepoint: Baseline, Day 90, Day 180,Day 360;Change from baseline to the end of the study period in Core LowerUrinary Tract Symptom score (CLSS | — |
Countries
India
Contacts
Public ContactShilpa K
Eetho Brands Inc (DBA: Dose)
Outcome results
None listed